BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature

Authors

Patricia Guerrero
Víctor Albarrán
María San Román
Carlos González-Merino
Coral García de Quevedo
Jaime Moreno
Juan Carlos Calvo
Guillermo González
Inmaculada Orejana
Jesús Chamorro
Íñigo Martínez-Delfrade
Blanca Morón
Belén de Frutos
María Reyes Ferreiro

Publication Date

10-31-2023

Journal

Cancers

DOI

10.3390/cancers15215243

PMID

37958416

PMCID

PMC10649848

PubMedCentral® Posted Date

10-31-2023

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Keywords

BRAF, inhibitors, resistance, colorectal cancer

Abstract

Metastatic colorectal cancer (mCRC) with mutated BRAF exhibits distinct biological and molecular features that set it apart from other subtypes of CRC. Current standard treatment for these tumors involves a combination of chemotherapy (CT) and VEGF inhibitors. Recently, targeted therapy against BRAF and immunotherapy (IT) for cases with microsatellite instability (MSI) have been integrated into clinical practice. While targeted therapy has shown promising results, resistance to treatment eventually develops in a significant portion of responsive patients. This article aims to review the available literature on mechanisms of resistance to BRAF inhibitors (BRAFis) and potential therapeutic strategies to overcome them.

Comments

Associated Data